Small molecule high throughput screen using AstraZeneca facilities
Chemical Biology, Pharmacology, Medicinal Chemistry and research grant from Medical Research Council (UKRI)
Apply by Thursday, Jan 28 at 16:00 UTC
About
Support for academic researchers to conduct high-throughput screening using AstraZeneca’s compound library and screening infrastructure. The January 2027 round is open to all targets and provides awards up to GBP270,000. Projects must be directed by an eligible research lead actively engaged in the work. Commercial-led applications and collaborations involving additional commercial parties are excluded. Apply through UKRI’s Funding Service by 28 January 2027 at 16:00 UK time.
Eligibility
Career stage: Not stated
Institution applies
Host location: United Kingdom, Gambia, Uganda
Reviewed Sep 24, 2026. Check the funder’s full conditions before applying.
Organisations with standard MRC eligibility; normally UK-based project leads, with the stated MRC Gambia and Uganda unit exceptions. One application per project lead; source rules restrict resubmissions.
Topics
Related funding
AstraZeneca Non-Clinical PhD Studentship in Next-generation TPD for oncology: Harnessing ubiquitin-independent pathways
Closes Nov 16University of CambridgeComputational Approaches to Curation at Scale for Biomedical Research Assets (R01 Clinical Trial Not Allowed)
Closes Jan 15, 2027National Institutes of Health
Open funding in Chemical Biology
All fundingERC Consolidator Grant 2027
Closes Jan 12, 2027European Research Council
Source: ukri.org